Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-07-28 Director's Dealing
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing Classification · 100% confidence The document text explicitly contains the header 'FORM 4' and 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES'. Form 4 is the standard SEC filing used by corporate insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS.
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly mentions 'Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000'. The content is a notification about an 'Interested party transaction - Rubin' and states 'Attached hereto is a report on *Interested party transaction - Rubin* *20240728Form4Rubin_isa.pdf*'. Since the document itself is short and serves primarily to announce the publication of an attached, specific report (which appears to be a Form 4 related filing, though the primary classification must come from the provided list), it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing a regulatory document attachment, RPA is a strong candidate, but since the content relates to a specific transaction/disclosure rather than just the timing of a standard report (like an Annual Report), and it is an 'Immediate Report' from a foreign issuer, it falls under the general regulatory announcement category. However, the core function here is announcing the availability of a specific attached report. If the attached report were a standard filing (like 10-K or IR), RPA would be correct. Since this is a specific disclosure about an interested party transaction, and it is being broadcast immediately via the regulatory system (MAGNA), it is best classified as a general Regulatory Filing (RNS) as it doesn't fit the other specific categories like DIRS (Director's Dealing) or LTR (Legal Proceedings), although it is related to insider/related party activity. Given the structure of announcing an attached document, RPA is also highly plausible. I will select RNS as the most appropriate general regulatory announcement fallback for specific, non-standard disclosures announced immediately.
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Director's Dealing Classification · 98% confidence The document explicitly contains the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners) pursuant to Section 16 of the Securities Exchange Act of 1934. This directly corresponds to Director's Dealing (insider trades). Although the definition for DIRS is 'Report of personal share transactions by company directors and executives (insider trades)', the specific SEC form for this activity is Form 4. Since the provided classification codes do not include a specific code for Form 4, I must select the closest matching category based on the content description. DIRS is the most appropriate fit for insider transaction reporting.
2024-07-28 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly mentions 'Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000'. The core content states: 'Attached hereto is a report on*Interested party transaction - Nabel* *20240728Form4Nabel_isa.pdf*'. Since the document itself is an announcement stating that a specific report (related to an interested party transaction) is attached, and it does not contain the full details of that transaction report, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of reporting an attached document, RPA is more precise than the general RNS fallback. However, 'Interested party transaction' reports often fall under specific disclosure rules that might map to a more specific category if available. Reviewing the definitions, none perfectly match 'Interested Party Transaction Disclosure'. Since this is a regulatory filing announcing the publication of a specific report, and it is not a standard 10-K, ER, or IR, it is best classified as a general Regulatory Filing (RNS) or RPA. Given the structure is an announcement of an attached document, RPA is appropriate, but RNS is often used for miscellaneous regulatory disclosures not covered elsewhere. Since the document is short and announces the publication of another document, RPA is the best fit based on Rule 2.
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Director's Dealing Classification · 100% confidence The document explicitly contains the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934". Form 4 is the standard SEC filing used by insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of company securities. This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-07-28 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Interested party transaction - Logal* *20240728Form4Logal_isa.pdf*'. This structure—a brief announcement stating that a specific report (in this case, related to an interested party transaction) is attached or published—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself, but the notice of its publication. The length (1789 chars) also supports this being a short announcement rather than a comprehensive filing like a 10-K or IR.
2024-07-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.